Brought to you by 
PregLem gains additional rights to HRA Pharma's Esmya
06 Dec 2011
Executive Summary
PregLem SA has licensed US and Canadian development and marketing rights to fellow women's health products developer HRA Pharma's Esmya (ulipristal) for benign gynecological disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PregLem gains additional rights to HRA Pharma's Esmya
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice